March 21, 2016

IMPORTANT DRUG WARNING

Subject: Decreased overall survival and increased risk of serious infections in patients receiving ZYDELI G® (idelalisib)

Dear Health Care Provider,

The purpose of this letter is to inform you of new important safety information for ZYDELIG.

Risk of Fatal and Serious Events with ZYDELIG Treatment in Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (iNHL)

Decreased overall survival and increased rates of serious adverse events (SAEs) have been observed in patients receiving ZYDELIG compared to the control groups in three ongoing Phase 3 studies evaluating the addition of ZYDELIG to standard therapies in first line CLL and relapsed iNHL/small lymphocytic lymphoma (SLL). The majority of events were infections, which included sepsis and pneumonia.

<table>
<thead>
<tr>
<th>Combined Studies 123/124/125</th>
<th>ZYDELIG (N = 664)</th>
<th>Control (N = 402)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Deaths</td>
<td>49 (7.4%)</td>
<td>14 (3.5%)</td>
</tr>
<tr>
<td>Hazard Ratio (95% CI)</td>
<td>2.29 (1.26, 4.18)</td>
<td></td>
</tr>
</tbody>
</table>

Gilead is stopping seven clinical trials in patients with CLL, SLL and iNHL.

Health Care Provider Action

ZYDELIG should not be used for first line treatment of CLL.

ZYDELIG is currently approved for the treatment of:

- Relapsed chronic lymphocytic leukemia, in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
- Relapsed follicular B-cell non-Hodgkin lymphoma in patients who have received at least two prior systemic therapies
- Relapsed small lymphocytic lymphoma in patients who have received at least two prior systemic therapies

For patients taking ZYDELIG:

- Counsel patients about the risk of serious and/or fatal infections
- Administer prophylaxis for Pneumocystis pneumonia (PCP/PJP) to all patients throughout ZYDELIG treatment. Monitor patients for cytomegalovirus (CMV) and permanently discontinue ZYDELIG in patients with evidence of infection or viremia (positive PCR or antigen test)
Monitor blood counts in all patients at least every 2 weeks for the first 6 months of treatment with ZYDELIG, and at least weekly in patients while absolute neutrophil count is less than 1000 per mm$^3$.

This information is based on currently available data and recommendations may change. Additionally, the ZYDELIG United States Prescribing Information (USPI) and Risk Evaluation and Mitigation Strategy (REMS) will be updated.

**Reporting Adverse Events**

Please report all adverse events, following or coincident with the use of ZYDELIG, to Gilead Global Drug Safety at 1-800-GILEAD-5, option 3; or to FDA’s MedWatch program by telephone at 1-800-332-1088; by fax at 1-800-332-0178; via www.FDA.gov/medwatch; or by mail to MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20857 (use postage-paid FDA Form 3500).

Please refer to the accompanying full prescribing information and approved patient information for a complete description of the risk profile for ZYDELIG.

Contact Gilead Medical Information at 1-800-GILEAD-5, option 2 if you have additional questions.

This information is being sent in agreement with the FDA.

Sincerely,

[Signature]

John McHutchison, MD
Executive Vice President, Clinical Research
Gilead Sciences, Inc.